SteadyMed Ltd. (NASDAQ:STDY) Files An 8-K Other Events
Item 8.01. Other Events.
On January9, 2017, SteadyMed Ltd. issued a press release titled
SteadyMed Outlines Strategic Goals and Priorities for 2017 and
Provides Update on Trevyent Launch Plans. A copy of the press
release is attached hereto as Exhibit99.1 and incorporated herein
by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
|
ExhibitDescription |
|
99.1 |
Press Release, dated January9, 2017 |
About SteadyMed Ltd. (NASDAQ:STDY)
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. Its product candidates are enabled by its PatchPump. Its Trevyent offers a way of administration of treprostinil for subcutaneous or intravenous treatment of PAH patients. The Company’s ketorolac At Home Patient Analgesia (AHPA) product candidate is used for the short-term (approximately five days) management of moderately severe acute pain that requires analgesia at the opioid level in a post-surgical setting. SteadyMed Ltd. (NASDAQ:STDY) Recent Trading Information
SteadyMed Ltd. (NASDAQ:STDY) closed its last trading session down -0.09 at 2.66 with 5,912 shares trading hands.